Scholarlink

Objectives <p>To compare the clinical and microbiological outcomes of high-risk neutropenic patients receiving or not fluoroquinolone prophylaxis.</p> Study eligibility criteria <p>Randomized controlled trials (RCTs) and observational studies investigating overall mortality and rate of febrile episodes, of bloodstream infections and of isolation of a fluoroquinolone-resistant strain among patients receiving or not prophylaxis.</p> Participants <p>Patients with high-risk neutropenia due to haematological malignancies.</p> Interventions <p>Prophylaxis with either ciprofloxacin or levofloxacin.</p> Comparator <p>&#xa0;No prophylaxis.</p> Methods of data synthesis <p>We conducted a meta-analysis pooling risk ratios (RRs) through random effect models.</p> Results <p>Among 1731 articles screened, 18 original studies fulfilled the inclusion criteria and were included in the analysis, accounting for a total of 12,586 patients, 7157 (56.9%) of which receiving fluoroquinolones prophylaxis. The analysis assessing the primary outcome including 12,134 patients showed similar mortality rates between groups (RR 1.04, 95% CI 0.79–1.37, <i>p</i> = 0.77), with a low statistical heterogeneity observed (I<sup>2</sup> 49.4%, <i>p</i> = 0.022). These findings were confirmed (RR 1.16, 95% CI 0.89–1.50, <i>p</i> = 0.27) in the sub-analysis excluding studies conducted in settings with low prevalence of fluoroquinolone resistance, on a total of 3121 patients, and a low heterogeneity was observed (I<sup>2</sup> 27.6%, <i>p</i> = 0.18). Regarding the incidence of febrile episodes, a lower rate was observed among the 1701 patients receiving prophylaxis as compared to the 1514 not receiving prophylaxis (RR 0.87, 95% CI 0.88–0.96, <i>p</i> = 0.006); similarly, a lower rate of bloodstream infections was demonstrated among subjects receiving fluoroquinolone prophylaxis (RR 0.59, 95% CI 0.47–0.75, <i>p</i> &lt; 0.001) in a meta-analysis including 11,681 patients. Finally, no difference in the isolation rate of fluoroquinolone resistant strains was observed (RR 0.87, 95% CI 0.34–2.20, <i>p</i> = 0.77) among 1481 patients included.</p> Conclusions <p>Our data suggest that fluoroquinolone prophylaxis in high-risk neutropenic patients is associated with a reduction in the incidence of febrile episodes and bacteraemia but does not provide a survival benefit.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of fluoroquinolone prophylaxis in high-risk neutropenic patients with haematological malignancies: a systematic review with meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • Lorenzo Onorato,
  • Margherita Macera,
  • Mariagrazia Palamone,
  • Francesca Ambrisi,
  • Nicola Coppola

摘要

Objectives

To compare the clinical and microbiological outcomes of high-risk neutropenic patients receiving or not fluoroquinolone prophylaxis.

Study eligibility criteria

Randomized controlled trials (RCTs) and observational studies investigating overall mortality and rate of febrile episodes, of bloodstream infections and of isolation of a fluoroquinolone-resistant strain among patients receiving or not prophylaxis.

Participants

Patients with high-risk neutropenia due to haematological malignancies.

Interventions

Prophylaxis with either ciprofloxacin or levofloxacin.

Comparator

 No prophylaxis.

Methods of data synthesis

We conducted a meta-analysis pooling risk ratios (RRs) through random effect models.

Results

Among 1731 articles screened, 18 original studies fulfilled the inclusion criteria and were included in the analysis, accounting for a total of 12,586 patients, 7157 (56.9%) of which receiving fluoroquinolones prophylaxis. The analysis assessing the primary outcome including 12,134 patients showed similar mortality rates between groups (RR 1.04, 95% CI 0.79–1.37, p = 0.77), with a low statistical heterogeneity observed (I2 49.4%, p = 0.022). These findings were confirmed (RR 1.16, 95% CI 0.89–1.50, p = 0.27) in the sub-analysis excluding studies conducted in settings with low prevalence of fluoroquinolone resistance, on a total of 3121 patients, and a low heterogeneity was observed (I2 27.6%, p = 0.18). Regarding the incidence of febrile episodes, a lower rate was observed among the 1701 patients receiving prophylaxis as compared to the 1514 not receiving prophylaxis (RR 0.87, 95% CI 0.88–0.96, p = 0.006); similarly, a lower rate of bloodstream infections was demonstrated among subjects receiving fluoroquinolone prophylaxis (RR 0.59, 95% CI 0.47–0.75, p < 0.001) in a meta-analysis including 11,681 patients. Finally, no difference in the isolation rate of fluoroquinolone resistant strains was observed (RR 0.87, 95% CI 0.34–2.20, p = 0.77) among 1481 patients included.

Conclusions

Our data suggest that fluoroquinolone prophylaxis in high-risk neutropenic patients is associated with a reduction in the incidence of febrile episodes and bacteraemia but does not provide a survival benefit.